Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Study sponsor: Belite Bio, Inc · BLTE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-04Actual
Enrollment · participants104Actual
Source updated2026-07-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.